CavitoMod-UTMDNet: A Mechanistic Cavitation-Diffusion Framework for Ultrasound-Targeted Microbubble Destruction-Enhanced Liposomal Doxorubicin Delivery in Pancreatic Cancer.

Pancreatic ductal adenocarcinoma (PDAC) has one of the poorest treatment responses since it contains desmoplastic stroma, lacks good vascularity, and has high interstitial fluid pressures, which are the most damaging factors depriving chemotherapy. Liposomal doxorubicin is much better in terms of systemic pharmacokinetics but is not efficient in PDAC due to the significant barrier of nanoparticles-stromal and vascular barriers. In a bid to eliminate these shortcomings, this paper presents CavitoMod-UTMDNet, which is an integrated mechanistic and experimental platform capable of utilizing ultrasound-targeted masterpiece unaffiliating (UTMD) as a means of temporarily improving vascular and stromal permeability and better intratumoral delivery of liposomal doxorubicin. The model combines Rayleigh-Plesset cavitation modeling and Fickian diffusion analysis with a two-compartment pharmacokinetic model and systematic in vitro and in vivo validation. Passive cavitation detection was used to establish stable cavitation exposure windows within FDA-acceptable mechanical index limits. UTMD increased intracellular drug uptake 3.2-3.8fold and reduced IC 0 in PANC-1 and BxPC-3 pancreatic cancer cell lines by around 50% in the presence of a stable cavitation (MI 1.2). UTMD progressively improved the level of intratumor drug delivery in the orthotopic immunodeficient mouse models (NU/NU strain) (2.4-fold) and led to a 54% decrease in tumor volume 21 days later without any trace of hepatic, renal, and cardiac toxicity. There were strong links between cavitation energy density and drug uptake and diffusion depth and therapeutic response as evidence that there is a mechanistic character to UTMD-enhanced actions. It will support the drug development in a better way. CavitoMod-UTMDNet is a combined strategy to maximize ultrasound-enhanced nanocarrier (nanoparticles) delivery using a physics-based reproducible plan to optimize ultrasound-enhanced nanocarrier delivery in PDAC that will see improvement in future translation to image-guided therapeutic strategies.